Recent News
Jan 11, 2026 — IDEAYA presented corporate objectives at the J.P. Morgan Healthcare Conference, announcing Q1 2026 topline progression-free survival (PFS) data expectations from the Phase 2/3 OptimUM‑02 darovasertib + crizotinib trial and multiple planned IND starts and registrational milestones for 2026.
Nov 28, 2025 — The company granted inducement stock options to a newly hired employee under its 2023 inducement plan, with an exercise price set at the closing market price on the grant date.
Technical Analysis
Directional indicators (ADX/DI+/DI-): ADX at 18.34 signals no established trend. DI+ at 17.73 shows a decreasing path, indicating short-term bearish pressure; DI- at 26.16 registered a peak-and-reversal, which carries a bullish implication that negative directional pressure has begun to abate.
MACD: MACD sits at -0.62 and the MACD line trades below the signal line (-0.34) while trending lower, a bearish momentum profile that suggests continuation of recent downside momentum absent an abrupt MACD crossover above the signal line.
MRO (Momentum/Regression Oscillator): MRO at -7.04 indicates the current price rests below the model target and therefore carries potential for upward mean reversion; the MRO trend shows a dip-and-reversal, supporting the potential for a move toward target levels over intermediate timeframes.
RSI: RSI at 50.4 with a decreasing trend points to neutral momentum that has softened; readings near 50 imply neither overbought nor oversold conditions but weakening short-term internals.
Price vs averages and bands: Last close $31.90 sits below the 20-day average ($33.28), the 12-day EMA ($33.14), the 26-day EMA ($33.87) and the 50-day average ($34.60), signaling short-term pressure; price remains above the 200-day average ($27.25), preserving the longer-term uptrend anchor. Bollinger bands place the 1x lower band at $32.08 and 2x lower at $30.87, with current price between those bands, suggesting compression near short-term support levels.
Ichimoku and volatility: Tenkan‑Sen ($33.67) and Kijun‑Sen ($35.20) both exceed the current price, implying short-term resistance; Senkou A ($34.67) above Senkou B ($31.64) retains a bullish cloud structure, but price below the cloud confirms the present short-term corrective phase. 42‑ and 52‑week volatilities at ~3% indicate relatively muted realized volatility versus typical biotech swings.
Fundamental Analysis
Profitability and cash: Operating income (EBIT) $108,452,000 and EBITDA $109,482,000 produce an operating margin of 52.18% and return on sales 52.18%, both consistent with the high-margin profile reflected in operating metrics. Cash and short‑term investments total $786,894,000 and cash alone $298,927,000, providing a strong liquidity buffer versus $27,245,000 total debt and a current ratio of 12.44x. Free cash flow $142,172,000 yields ~6.01% free cash flow yield on market capitalization, supporting runway and program funding.
Growth and R&D: Total revenue $207,834,000 and YoY revenue growth 28.69% show meaningful top-line expansion; research and development expense $82,993,000 underscores continued pipeline investment. Net income $119,244,000 produces EPS actual $1.33 versus an EPS estimate of -$0.55, an EPS surprise (difference) of $1.88 indicating a positive earnings variance for the reported period.
Capital structure and returns: Debt metrics remain light — debt-to-equity 0.02495 and debt-to-assets 0.02299 — while return on equity 10.92% and return on assets 10.71% indicate productive use of capital. Interest coverage ratio 4.33x signals ability to service interest expense from operating earnings.
Valuation metrics: Price/earnings at 20.28x and price/book 2.16x present a valuation below certain peer medians; price/sales 11.38x and enterprise multiple ~14.66x reflect premium expectations tied to clinical value. WMDST values the stock as under-valued given cash runway, operating profitability and near-term registrational catalysts.
Industry comparisons where provided: Operating margin (52.18%) stands above the industry peer mean (-0.84%) and median (0.42%). Price/book (2.16x) sits below the industry peer mean (6.90). Price/earnings (20.28x) sits below the industry peer median (30.96). Free cash flow yield (~6.01%) exceeds the industry peer mean (0.59%). These comparisons indicate stronger profitability and cash conversion against the industry peer mean while market multiples sit below peer central tendencies.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-09-30 |
| REPORT DATE: | 2025-11-04 |
| NEXT REPORT DATE: | 2026-02-03 |
| CASH FLOW | Begin Period Cash Flow | $ 115.5 M |
| Operating Cash Flow | $ 142.2 M | |
| Capital Expenditures | $ -42.00 K | |
| Change In Working Capital | $ 11.7 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 184.3 M | |
| End Period Cash Flow | $ 299.7 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 207.8 M | |
| Forward Revenue | $ -34.01 M | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | $ 1.0 M | |
| Depreciation and Amortization | $ 1.0 M | |
| Research and Development | $ 83.0 M | |
| Total Operating Expenses | $ 99.4 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ 109.5 M | |
| EBIT | $ 108.5 M | |
| Operating Income | $ 108.5 M | |
| Interest Income | $ 10.8 M | |
| Interest Expense | — | |
| Net Interest Income | $ 10.8 M | |
| Income Before Tax | $ 119.2 M | |
| Tax Provision | — | |
| Tax Rate | 21.0 % | |
| Net Income | $ 119.2 M | |
| Net Income From Continuing Operations | $ 119.2 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.55 | |
| EPS Actual | $ 1.33 | |
| EPS Difference | $ 1.88 | |
| EPS Surprise | 341.818 % | |
| Forward EPS | $ -0.89 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 1.2 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 1.1 B | |
| Total Current Assets | $ 802.7 M | |
| Cash and Short-Term Investments | $ 786.9 M | |
| Cash | $ 298.9 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | $ 805.0 K | |
| LIABILITIES | ||
| Accounts Payable | $ 18.4 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 64.5 M | |
| Net Debt | — | |
| Total Debt | $ 27.2 M | |
| Total Liabilities | $ 93.1 M | |
| EQUITY | ||
| Total Equity | $ 1.1 B | |
| Retained Earnings | $ -653.27 M | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 12.46 | |
| Shares Outstanding | 87.666 M | |
| Revenue Per-Share | $ 2.37 | |
| VALUATION | Market Capitalization | $ 2.4 B |
| Enterprise Value | $ 1.6 B | |
| Enterprise Multiple | 14.655 | |
| Enterprise Multiple QoQ | -193.146 % | |
| Enterprise Multiple YoY | -149.007 % | |
| Enterprise Multiple IPRWA | high: 52.77 median: 28.451 IDYA: 14.655 mean: 8.453 low: -82.433 |
|
| EV/R | 7.72 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.085 | |
| Asset To Liability | 12.729 | |
| Debt To Capital | 0.024 | |
| Debt To Assets | 0.023 | |
| Debt To Assets QoQ | -9.984 % | |
| Debt To Assets YoY | 51.649 % | |
| Debt To Assets IPRWA | high: 1.045 mean: 0.24 median: 0.181 IDYA: 0.023 low: 0.0 |
|
| Debt To Equity | 0.025 | |
| Debt To Equity QoQ | -9.993 % | |
| Debt To Equity YoY | 56.721 % | |
| Debt To Equity IPRWA | high: 1.461 mean: 0.342 median: 0.106 IDYA: 0.025 low: -0.897 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 2.165 | |
| Price To Book QoQ | 2.798 % | |
| Price To Book YoY | -11.001 % | |
| Price To Book IPRWA | high: 16.86 mean: 6.904 median: 6.057 IDYA: 2.165 low: -8.555 |
|
| Price To Earnings (P/E) | 20.276 | |
| Price To Earnings QoQ | -181.484 % | |
| Price To Earnings YoY | -136.589 % | |
| Price To Earnings IPRWA | high: 56.753 median: 30.96 IDYA: 20.276 mean: 4.573 low: -93.179 |
|
| PE/G Ratio | -0.081 | |
| Price To Sales (P/S) | 11.375 | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | high: 1040.421 mean: 64.81 median: 18.442 IDYA: 11.375 low: 0.466 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | -35.568 | |
| Forward PE/G | 0.142 | |
| Forward P/S | -91.015 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.187 | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | high: 0.438 IDYA: 0.187 mean: 0.119 median: 0.107 low: -0.004 |
|
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | high: 520.898 median: 189.366 mean: 166.152 IDYA: 0 low: -314.885 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.282 | |
| CapEx To Revenue | -0.0 | |
| CapEx To Depreciation | -0.041 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.1 B | |
| Net Invested Capital | $ 1.1 B | |
| Invested Capital | $ 1.1 B | |
| Net Tangible Assets | $ 1.1 B | |
| Net Working Capital | $ 738.1 M | |
| LIQUIDITY | ||
| Cash Ratio | 12.198 | |
| Current Ratio | 12.443 | |
| Current Ratio QoQ | 0.429 % | |
| Current Ratio YoY | -45.731 % | |
| Current Ratio IPRWA | high: 25.502 IDYA: 12.443 mean: 4.03 median: 2.865 low: 0.02 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | 0.249 | |
| Cost Of Debt | 73.559 % | |
| Interest Coverage Ratio | 4.326 | |
| Interest Coverage Ratio QoQ | -222.122 % | |
| Interest Coverage Ratio YoY | -262.128 % | |
| Interest Coverage Ratio IPRWA | high: 815.709 mean: 37.741 median: 6.583 IDYA: 4.326 low: -1337.523 |
|
| Operating Cash Flow Ratio | 1.882 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 13.816 % | |
| Revenue Growth | 2869.057 % | |
| Revenue Growth QoQ | — | |
| Revenue Growth YoY | — | |
| Revenue Growth IPRWA | IDYA: 2869.057 % high: 301.849 % mean: 8.063 % median: 4.118 % low: -259.856 % |
|
| Earnings Growth | -251.136 % | |
| Earnings Growth QoQ | -3532.226 % | |
| Earnings Growth YoY | 2034.603 % | |
| Earnings Growth IPRWA | high: 162.5 % median: -6.312 % mean: -8.527 % low: -198.545 % IDYA: -251.136 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | 52.182 % | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | high: 3270.865 % IDYA: 52.182 % median: 42.305 % mean: -84.246 % low: -7772.481 % |
|
| Return On Sales (ROS) | 52.182 % | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | high: 573.037 % IDYA: 52.182 % median: 26.431 % mean: -90.032 % low: -7977.249 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ 142.2 M | |
| Free Cash Flow Yield | 6.014 % | |
| Free Cash Flow Yield QoQ | -292.51 % | |
| Free Cash Flow Yield YoY | -447.429 % | |
| Free Cash Flow Yield IPRWA | high: 30.655 % IDYA: 6.014 % median: 1.086 % mean: 0.588 % low: -57.887 % |
|
| Free Cash Growth | -325.18 % | |
| Free Cash Growth QoQ | -13791.789 % | |
| Free Cash Growth YoY | -795.186 % | |
| Free Cash Growth IPRWA | high: 201.164 % mean: 25.288 % median: 22.832 % low: -200.947 % IDYA: -325.18 % |
|
| Free Cash To Net Income | 1.192 | |
| Cash Flow Margin | 58.43 % | |
| Cash Flow To Earnings | 1.018 | |
| VALUE & RETURNS | ||
| Economic Value Added | $ 0.05 | |
| Return On Assets (ROA) | 10.712 % | |
| Return On Assets QoQ | -248.038 % | |
| Return On Assets YoY | -328.791 % | |
| Return On Assets IPRWA | high: 30.5 % IDYA: 10.712 % median: 2.314 % mean: -1.397 % low: -66.968 % |
|
| Return On Capital Employed (ROCE) | 9.678 % | |
| Return On Equity (ROE) | 0.109 | |
| Return On Equity QoQ | -235.22 % | |
| Return On Equity YoY | -348.724 % | |
| Return On Equity IPRWA | high: 0.948 IDYA: 0.109 median: 0.047 mean: 0.013 low: -1.385 |
|
| DuPont ROE | 11.624 % | |
| Return On Invested Capital (ROIC) | 7.846 % | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | 5.713 % | |
| Return On Invested Capital IPRWA | high: 31.965 % IDYA: 7.846 % median: 5.759 % mean: 0.934 % low: -73.241 % |
|